Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M, Schwarz J, Ovesná P, Cervinek L, Dulíček P, Pospíšilová D, Kissová J, Pavlík T; kolektiv Ceske pracovni skupiny pro myeloproliferativni choroby (CZEMP). Penka M, et al. Vnitr Lek. 2013 Jun;59(6):516-31. Vnitr Lek. 2013. PMID: 23808749 Czech.
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M, Doubek M, Schwarz J, Pytlík R, Dulícek P, Kissová J, Hlusí A, Vozobulová V, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Schutzová M, Hadacová I, Hochová I, Voglová J, Siroký O, Belada D, Lhot'anová T, Bubeník B, Vránová M, Micaníková M, Dusek L. Penka M, et al. Vnitr Lek. 2006 May;52(5):498-503. Vnitr Lek. 2006. PMID: 16771099 Czech.
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulícek P, Pospísilová D, Kissová J, Hlusí A, Schützová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Lhotanová T, Bubeník B, Zapletal O, Vránová M, Micaníková M, Dusek L. Penka M, et al. Vnitr Lek. 2007 Jun;53(6):653-61. Vnitr Lek. 2007. PMID: 17702125 Czech.
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine].
Penka M, Schwarz J, Pavlík T, Pytiĺk R, Doubek M, Dulícek P, Kissová J, Hlusi A, Schutzová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Dusek L. Penka M, et al. Vnitr Lek. 2008 Jul-Aug;54(7-8):775-82. Vnitr Lek. 2008. PMID: 18780577 Czech.
[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
Penka M, Schwarz J, Campr V, Pospíšilová D, Křen L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulíček P, Jonášová A, Kissová J, Kořístek Z, Schützová M, Vonke I, Walterová L; Czech Working Group of the Czech Hematologic Society CLS JEP. Penka M, et al. Vnitr Lek. 2012 Feb;58(2):163-8. Vnitr Lek. 2012. PMID: 22463098 Czech. No abstract available.
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
Penka M, Schwarz J, Pavlík T, Indrák K, Doubek M, Dulícek P, Pospísilová D, Kissová J, Jonásová A, Jelínková P, Hlusí A, Schutzová M, Cerná O, Brychtová Y, Nováková L, Korístek Z, Segethová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Walterová L, Bodzásová C, Dusek L. Penka M, et al. Vnitr Lek. 2009 Nov;55(11):I-XII. Vnitr Lek. 2009. PMID: 20017445 Clinical Trial. Czech.
[The place of JAK2 inhibitors in the treatment of myelofibrosis. An amendment to the recommendations for diagnosis and treatment of Ph negative myeloproliferations of the Czech group for Ph- myeloproliferative disorders (CZEMP)].
Červinek L, Doubek M, Penka M, Schwarz J; Česká Pracovní Skupina pro Ph Negativní Myeloproliferativní onemocnění. Červinek L, et al. Among authors: penka m. Vnitr Lek. 2014 Feb;60(2):158-63. Vnitr Lek. 2014. PMID: 24754420 Czech.
179 results